Published studies of the clinical validity of BRAF p.Val600Glu testing were retrospective analyses of patients treated with cetuximab or panitumumab at cancer treatment centers[19], [39], [40], [41], [42], [43] or a cohort of patients that had been in one of three clinical trials[44](see Table 1). Here, BRAF is linked to cancer.